MX2023014359A - Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico. - Google Patents
Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico.Info
- Publication number
- MX2023014359A MX2023014359A MX2023014359A MX2023014359A MX2023014359A MX 2023014359 A MX2023014359 A MX 2023014359A MX 2023014359 A MX2023014359 A MX 2023014359A MX 2023014359 A MX2023014359 A MX 2023014359A MX 2023014359 A MX2023014359 A MX 2023014359A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- pyrazole
- cyano
- isopropyl
- carboxylic acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 title abstract 2
- 201000001431 Hyperuricemia Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-ca rboxílico o una sal farmacéuticamente aceptable de este, y un método para tratar o prevenir una enfermedad relacionada con la hiperuricemia usándolo, y la composición farmacéutica de la presente invención puede reducir de manera eficaz la concentración de ácido úrico en sangre en un paciente con una enfermedad relacionada con la hiperuricemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210077709 | 2021-06-15 | ||
| PCT/KR2022/008444 WO2022265378A1 (ko) | 2021-06-15 | 2022-06-15 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014359A true MX2023014359A (es) | 2023-12-15 |
Family
ID=84525806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014357A MX2023014357A (es) | 2021-06-15 | 2022-06-15 | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo. |
| MX2023014359A MX2023014359A (es) | 2021-06-15 | 2022-06-15 | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014357A MX2023014357A (es) | 2021-06-15 | 2022-06-15 | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20240285583A1 (es) |
| EP (2) | EP4344701A4 (es) |
| JP (2) | JP2024520150A (es) |
| KR (2) | KR20220168172A (es) |
| CN (2) | CN117412746A (es) |
| AR (1) | AR126153A1 (es) |
| AU (2) | AU2022294728A1 (es) |
| BR (2) | BR112023026415A2 (es) |
| CA (2) | CA3221533A1 (es) |
| CL (2) | CL2023003514A1 (es) |
| CO (2) | CO2023016621A2 (es) |
| MX (2) | MX2023014357A (es) |
| PE (2) | PE20240241A1 (es) |
| PH (1) | PH12023553231A1 (es) |
| TW (1) | TWI888729B (es) |
| WO (2) | WO2022265382A1 (es) |
| ZA (2) | ZA202311241B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2133332B1 (en) * | 2007-04-11 | 2013-09-18 | Kissei Pharmaceutical Co., Ltd. | (aza)indole derivative and use thereof for medical purposes |
| TWI423962B (zh) | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| TWI548630B (zh) | 2011-04-06 | 2016-09-11 | Ｌｇ生命科學有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 |
| JP2016520133A (ja) * | 2013-05-31 | 2016-07-11 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物 |
| JP2015160847A (ja) * | 2014-02-28 | 2015-09-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 小分子のキサンチンオキシダーゼ阻害剤および使用方法 |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| SG11202103078WA (en) | 2018-10-01 | 2021-04-29 | Astrazeneca Ab | Compositions for reducing serum uric acid |
| PE20240222A1 (es) | 2020-12-01 | 2024-02-16 | Lg Chemical Ltd | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion |
-
2022
- 2022-06-15 KR KR1020220072501A patent/KR20220168172A/ko not_active Ceased
- 2022-06-15 PE PE2023003210A patent/PE20240241A1/es unknown
- 2022-06-15 WO PCT/KR2022/008450 patent/WO2022265382A1/ko not_active Ceased
- 2022-06-15 US US18/569,571 patent/US20240285583A1/en active Pending
- 2022-06-15 AR ARP220101577A patent/AR126153A1/es not_active Application Discontinuation
- 2022-06-15 AU AU2022294728A patent/AU2022294728A1/en not_active Abandoned
- 2022-06-15 CA CA3221533A patent/CA3221533A1/en active Pending
- 2022-06-15 AU AU2022292402A patent/AU2022292402A1/en not_active Abandoned
- 2022-06-15 WO PCT/KR2022/008444 patent/WO2022265378A1/ko not_active Ceased
- 2022-06-15 KR KR1020220072509A patent/KR20220168173A/ko not_active Ceased
- 2022-06-15 EP EP22825305.0A patent/EP4344701A4/en not_active Withdrawn
- 2022-06-15 CN CN202280034026.0A patent/CN117412746A/zh active Pending
- 2022-06-15 MX MX2023014357A patent/MX2023014357A/es unknown
- 2022-06-15 JP JP2023574689A patent/JP2024520150A/ja not_active Ceased
- 2022-06-15 BR BR112023026415A patent/BR112023026415A2/pt unknown
- 2022-06-15 MX MX2023014359A patent/MX2023014359A/es unknown
- 2022-06-15 JP JP2023574504A patent/JP7668386B2/ja active Active
- 2022-06-15 BR BR112023026432A patent/BR112023026432A2/pt unknown
- 2022-06-15 EP EP22825301.9A patent/EP4360631A4/en active Pending
- 2022-06-15 CN CN202280039108.4A patent/CN117425477A/zh active Pending
- 2022-06-15 CA CA3221017A patent/CA3221017A1/en active Pending
- 2022-06-15 PH PH1/2023/553231A patent/PH12023553231A1/en unknown
- 2022-06-15 US US18/569,568 patent/US20240293369A1/en active Pending
- 2022-06-15 PE PE2023003221A patent/PE20240242A1/es unknown
- 2022-06-15 TW TW111122220A patent/TWI888729B/zh active
-
2023
- 2023-11-24 CL CL2023003514A patent/CL2023003514A1/es unknown
- 2023-11-24 CL CL2023003513A patent/CL2023003513A1/es unknown
- 2023-11-30 CO CONC2023/0016621A patent/CO2023016621A2/es unknown
- 2023-11-30 CO CONC2023/0016596A patent/CO2023016596A2/es unknown
- 2023-12-06 ZA ZA2023/11241A patent/ZA202311241B/en unknown
- 2023-12-06 ZA ZA2023/11237A patent/ZA202311237B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| DE60137635D1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| MX2023005533A (es) | Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| CN107028880A (zh) | 一种盐酸右美托咪定注射液的生产工艺 | |
| AU2021311245A8 (en) | Compound for androgen receptor degradation, and pharmaceutical use thereof | |
| ZA202311237B (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| RU2011123367A (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином | |
| TW200616644A (en) | Medicine for prevention or treatment of diabetes | |
| MD4802B1 (ro) | Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor | |
| PH12021553055A1 (en) | Methods and compositions for improving outcomes of cancer patients | |
| PH12022553388A1 (en) | Prophylactic or therapeutic agent for porphyria | |
| MX2024009413A (es) | Novedoso uso del agonista del receptor de melanocortina-1. | |
| NO20054096L (no) | Inhibitor for perioperativ blodsukkerforhoyelse | |
| Munerato et al. | Return of spontaneous circulation after cardiopulmonary arrest in an adult horse recovering from anaesthesia | |
| EP4619008A1 (en) | Hypochlorite solution for treating scar tissue | |
| ZA202502846B (en) | Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin | |
| WO2023183820A3 (en) | Respiratory tract infection therapeutics against covid-19 | |
| Kharb | Hypertension: case report | |
| TW200608965A (en) | Medicine for prevention or treatment of diabetes |